enliven therapeutics inc: Live & Latest News Updates : Vimarsana.com

Boulder's Enliven has cash runway into late 2026 – Boulder Daily Camera

Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder clinical-stage precision oncology company, has enough cash on hand to fund operations into late 2026, the company disclosed this week, and through multiple milestones for two of its drug candidates.

North American Morning Briefing : Traders Brace -2-

North American Morning Briefing: Traders Brace -2-

Enliven has cash runway into late 2026 – BizWest

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 1,000 Shares of Stock

Analyzing Enliven Therapeutics (NASDAQ:ELVN) & Processa Pharmaceuticals (NASDAQ:PCSA)

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Profitability This table compares Enliven Therapeutics and […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50. The transaction was disclosed in a document filed with the SEC, which is accessible […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) insider Joseph P. Lyssikatos sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $17.92, for a total value of $215,040.00. The transaction was disclosed in a legal filing with the Securities […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Up 9.7% in April

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,640,000 shares, an increase of 9.7% from the March 31st total of 4,230,000 shares. Based on an average trading volume of 247,800 shares, […]